Understanding the current therapeutic landscape for non-metastatic lung cancer in Queensland

No Thumbnail Available
File version
Author(s)
Chan, Bryan
Dhanda, Pardeep
Nath, Artika
Rawson, Neal
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2022
Size
File type(s)
Location

Brisbane, Australia

License
Abstract

Aims: To review current treatment trends in systemic therapy and examine outcomes for patients diagnosed with NSCLC. At risk patient populations, specifically, First Nations peoples, and those residing in rural and regional locations will be assessed against the state-wide population to highlight variances and opportunities for improvement in care.

Methods: Data were extracted from Qld Oncology Repository (QOR), a comprehensive repository which contains demographic, diagnosis, and treatment data on Queenslanders diagnosed with cancer. The study cohort includes patients diagnosed with stage I-IV NSCLC in 2011–2019.

Results: Optimal care pathways for lung cancer state that NSCLC patients receiving resection may also be candidates for neoadjuvant and adjuvant systemic therapy. The rate of neoadjuvant treatment for Non-First Nations peoples was 4%, and 2% for First Nations peoples. Similarly, the adjuvant systemic therapy rate for Non-First Nations peoples was 23% and 17% for First Nations peoples. Disparities in adjuvant treatment rates were also observed across residential location. For example, rates for patients living in a Major City was 25% but for those living in inner regional, outer regional and remote or very remote areas, was 23%, 17% and 16%, respectively. Mortality rates have decreased significantly, likely due to earlier screening programs and advancements in treatment therapies such as targeted and immunotherapies. However, variations in 2-year survival rates remain significant across stage (stage I, 85%, stage II, 65%, stage III, 45% and stage IV, 18%).

Conclusion: The vast and readily available cancer data through QOR has allowed for an in-depth analysis of treatment trends for at risk populations and an examination of survival outcomes for Queenslanders diagnosed with NSCLC. This analysis not only provides a foundation for quality improvement initiatives but also for ongoing reporting to ensure inequity in care provision is monitored and measured for all Queenslanders diagnosed with NSCLC.

Journal Title

Asia-Pacific Journal of Clinical Oncology

Conference Title

COSA's 49th Annual Scientific Meeting Equitable cancer care for all: Gender, identity, culture, geography, and disease should not matter

Book Title
Edition
Volume

18

Issue

S3

Thesis Type
Degree Program
School
DOI
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Oncology and carcinogenesis

Aboriginal and Torres Strait Islander public health and wellbeing

Life Sciences & Biomedicine

Oncology

Science & Technology

Persistent link to this record
Citation

Chan, B; Dhanda, P; Nath, A; Rawson, N, Understanding the current therapeutic landscape for non-metastatic lung cancer in Queensland, Asia-Pacific Journal of Clinical Oncology, 2022, 18 (S3), pp. 111-111